TY - JOUR
T1 - Precision medicine in clinical oncology
T2 - the journey from IgG antibody to IgE
AU - Fazekas-Singer, Judit
AU - Singer, Josef
AU - Jensen-Jarolim, Erika
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - PURPOSE OF REVIEW: Cancer is one of the leading causes of death and the incidence rates are constantly rising. The heterogeneity of tumors poses a big challenge for the treatment of the disease and natural antibodies additionally affect disease progression. The introduction of engineered mAbs for anticancer immunotherapies has substantially improved progression-free and overall survival of cancer patients, but little efforts have been made to exploit other antibody isotypes than IgG.RECENT FINDINGS: In order to improve these therapies, 'next-generation antibodies' were engineered to enhance a specific feature of classical antibodies and form a group of highly effective and precise therapy compounds. Advanced antibody approaches include among others antibody-drug conjugates, glyco-engineered and Fc-engineered antibodies, antibody fragments, radioimmunotherapy compounds, bispecific antibodies and alternative (non-IgG) immunoglobulin classes, especially IgE.SUMMARY: The current review describes solutions for the needs of next-generation antibody therapies through different approaches. Careful selection of the best-suited engineering methodology is a key factor in developing personalized, more specific and more efficient mAbs against cancer to improve the outcomes of cancer patients. We highlight here the large evidence of IgE exploiting a highly cytotoxic effector arm as potential next-generation anticancer immunotherapy.
AB - PURPOSE OF REVIEW: Cancer is one of the leading causes of death and the incidence rates are constantly rising. The heterogeneity of tumors poses a big challenge for the treatment of the disease and natural antibodies additionally affect disease progression. The introduction of engineered mAbs for anticancer immunotherapies has substantially improved progression-free and overall survival of cancer patients, but little efforts have been made to exploit other antibody isotypes than IgG.RECENT FINDINGS: In order to improve these therapies, 'next-generation antibodies' were engineered to enhance a specific feature of classical antibodies and form a group of highly effective and precise therapy compounds. Advanced antibody approaches include among others antibody-drug conjugates, glyco-engineered and Fc-engineered antibodies, antibody fragments, radioimmunotherapy compounds, bispecific antibodies and alternative (non-IgG) immunoglobulin classes, especially IgE.SUMMARY: The current review describes solutions for the needs of next-generation antibody therapies through different approaches. Careful selection of the best-suited engineering methodology is a key factor in developing personalized, more specific and more efficient mAbs against cancer to improve the outcomes of cancer patients. We highlight here the large evidence of IgE exploiting a highly cytotoxic effector arm as potential next-generation anticancer immunotherapy.
KW - Antibodies, Bispecific/therapeutic use
KW - Antibodies, Monoclonal/therapeutic use
KW - Antineoplastic Agents, Immunological/therapeutic use
KW - Drug Resistance, Neoplasm/genetics
KW - Humans
KW - Immunoconjugates/therapeutic use
KW - Immunoglobulin E/therapeutic use
KW - Immunoglobulin Fc Fragments/therapeutic use
KW - Medical Oncology/methods
KW - Neoplasms/drug therapy
KW - Precision Medicine/methods
KW - Progression-Free Survival
KW - Protein Engineering
KW - Radioimmunotherapy/methods
KW - Tumor Escape/genetics
KW - tumor-associated antigens
KW - allergooncology
KW - IgE
KW - immunotherapy of cancer
KW - antibody optimization approaches
UR - http://www.scopus.com/inward/record.url?scp=85084277279&partnerID=8YFLogxK
U2 - 10.1097/ACI.0000000000000637
DO - 10.1097/ACI.0000000000000637
M3 - Journal article
C2 - 32349107
SN - 1528-4050
VL - 20
SP - 282
EP - 289
JO - Current Opinion in Allergy and Clinical Immunology
JF - Current Opinion in Allergy and Clinical Immunology
IS - 3
ER -